logo

For the Inventor, By the Inventor

Sendai, Japan

Yasuo Fukushi

This inventor holds 3 USPTO granted patents. Top assignee: Fred Hutchinson Cancer Center. Active years: 1989-1992.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yasuo Fukushi. Retrieved from https://idiyas.com/inventor/yasuo-fukushi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 61(Granted Patents)


Company Filing History:

goldMedal3 out of 309 
 
Fred Hutchinson Cancer Center
 patents

Years Active: 1989-1992

Loading Chart...
3 patents (USPTO):Explore Patents
1. 5171667 - Hybridomas producing monoclonal antibodies to mono-, di- and (1992-12-15),
2. 5011920 - Disialofucoganglioside immunogen and fucoganglioside monosialosyl (1991-04-30),
3. 4851511 - Monoclonal antibody that specifically binds to disialosyl Le.sup.a (1989-07-25),

Title: Innovations in Cancer Research by Yasuo Fukushi

Introduction

Yasuo Fukushi is a prominent inventor based in Sendai, Japan, known for his significant contributions to cancer research. He has been instrumental in developing innovative hybridoma cell lines that produce monoclonal antibodies, which are crucial for cancer diagnosis and treatment. With a total of three patents to his name, Fukushi's work has the potential to impact the medical field significantly.

Latest Patents

Fukushi's latest patents focus on hybridomas that produce monoclonal antibodies targeting specific tumor cells characterized by unique fucosylated type 2 chain structures. These antibodies can detect tumor cells enriched in mono-, di-, or trifucosylated structures, making them valuable for diagnosing various cancers. Additionally, he has disclosed an improved method for raising hybridoma cell lines by selecting hybridomas that react positively with specific fucosylated type 2 chain structures. His work also includes the development of a novel human cancer-associated fucoganglioside, disialosyl Le^a, which has shown high immunogenicity and is detected in various cancer tissues.

Career Highlights

Fukushi is affiliated with the Fred Hutchinson Cancer Center, where he continues to advance his research in cancer immunology. His innovative approaches have led to the identification of biomarkers that can aid in early cancer detection and treatment strategies. His work is recognized for its potential to improve patient outcomes in oncology.

Collaborations

Fukushi has collaborated with notable researchers in the field, including Sen-itiroh Hakomori and Edward D Nudelman. These collaborations have further enriched his research and contributed to the advancement of cancer therapies.

Conclusion

Yasuo Fukushi's contributions to cancer research through his innovative patents and collaborative efforts highlight the importance of scientific advancements in improving cancer diagnosis and treatment. His work continues to pave the way for future innovations in the medical field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…